AUTHORS
Ross Firestone, MD/PhD, Tarek Mouhieddine, MD2, Zachary M. Avigan, MD, MHS3, Patrick Born, MD4, Amy H. H. Huang, MD5, Charalampos Charalampous, MD6, Mohammad Rattu, PharmD7, Santiago Thibaud, MD8, Larysa Sanchez, MD9, Joshua Richter I, MD10, Shambavi Richard, MD11, Adriana Rossi, MD12, Gurbakhash Kaur, MD13, Hearn Cho, MD, PhD14, Samir Parekh, MD15, Sundar Jagannath, M.D.16, Mark Bal, MD17, Shonali Midha, MD18, Adam S. Sperling, MD, PhD19, Poy Theprungsirikul, MD20, Yuxin Liu, MD21, Clifton C. Mo, MD22, Jacob Laubach, MD23, Nikhil Munshi, MD24, Paul G. Richardson, MD25, Kenneth Anderson, MD26, Sham Mailankody, MBBS27, Neha Korde, MD28, Carlyn Rose Tan, MD29, Hamza Hashmi, M.D.30, Malin Hultcrantz, MD PhD31, Francesco Maura, MD32, Maximilian Merz, MD33, Saad Z. Usmani, MD34, Cesar Rodriguez Valdes, MD35
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Universitat Leipzig, Leipzig, Germany
5 National Institutes of Health, Bethesda, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Dana Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana Farber Cancer Institute, Boston, Massachusetts, United States
21 Dana Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana Farber Cancer Institute, Boston, Massachusetts, United States
23 Dana Farber Cancer Institute, Boston, Massachusetts, United States
24 Dana Farber Cancer Institute, Boston, Massachusetts, United States
25 Dana Farber Cancer Institute, Boston, Massachusetts, United States
26 Dana Farber Cancer Institute, Boston, Massachusetts, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York, New York, United States
31 Memorial Sloan Kettering Cancer Center, New York, New York, United States
32 Memorial Sloan Kettering Cancer Center, New York, New York, United States
33 Memorial Sloan Kettering Cancer Center, New York, New York, United States
34 Memorial Sloan Kettering Cancer Center, New York, New York, United States
35 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Introduction: Bispecific antibodies (BsAbs) have transformed treatment for relapsed/refractory multiple myeloma (RRMM). Preclinical and ex vivo correlative studies suggest that unfavorable T cell characteristics are responsible for primary resistance, with T cell function seemingly worsening after relapse. Others demonstrate tumor antigen escape triggering secondary resistance. To determine whether resistance mechanisms are shared across BsAbs with different targets, we conducted an international, multi-center, retrospective analysis of RRMM patients treated with ≥2 BsAbs.
Methods: Patient demographics, disease characteristics, treatment history, and clinical outcomes were collected retrospectively in RRMM patients who received ≥2 lines of therapy with CD3-engaging BsAbs. Patients were included if they received their second BsAb (BsAb #2) prior to 07/01/2025, with a data-cutoff of 07/01/2026. Survival analysis was restricted to patients who received both BsAbs as single agents at the recommended phase 2 dose (RP2D).
Results: Across 4 institutions, we identified 187 patients who received ≥2 BsAbs. The median age at initiation of the first BsAb (BsAb #1) was 66 (range 36-86), 49% were male, and 50% had high-risk cytogenetics. Self-reported race was White in 66%, Black in 15%, Asian in 6%, and other in 13%, while 12% reported Hispanic ethnicity. Patients received a median of 6 lines of therapy prior to BsAb #1 (range 2-18). Common BsAbs were teclistamab, talquetamab, cevostamab, elranatamab, and linvoseltamab. The antigen target for BsAb #1 and #2 switched in 178/187 patients, most commonly BCMA->GPRC5D (89/187) and GPRC5D->BCMA (55/187). Across the full cohort, 7 patients received BsAb monotherapy against the same antigenic target for BsAb #1 and #2 (6 BCMA->BCMA, 1 GPRC5D->GPRC5D), only 1 of whom had a clinical response to BsAb #2, a patient treated with teclistamab following AMG-701 below its RP2D.
For survival analysis, 46 patients were excluded (due to receiving BsAb #1 or #2 below the RP2D or as part of combination therapy, or due to limited follow-up). Of the 141 patients eligible for survival analysis, 136 switched the antigen target between BsAb #1 and #2 and 63/141 had BCMA-directed CART or ADC therapy prior to BsAb #1 (70/141 prior to BsAb #2). Among the 136 patients whose antigen target changed between BsAb #1 and #2, paired progression-free survival (PFS) analysis showed that PFS with BsAb #1 (PFSa) was comparable to PFS with BsAb #2 (PFSb) (median PFS 138 vs 127 days; 6-month restricted mean PFS 116 vs 110 days, p = 0.52; 1-year restricted mean PFS 161 vs 169 days, p = 0.60). A strong response to BsAb #1, whether by IMWG criteria (≥VGPR) or by duration of response (PFSa ≥6 months), was not significantly predictive of PFSb (p = 0.10 and 0.13), nor was duration of therapy with BsAb #1 above vs below the median of 124 days (p = 0.36). There was no PFSb benefit associated with a longer BsAb therapy-free interval (≥90 or ≥180 days; p = 0.16, 0.54). PFSb was worse when BsAb #2 targeted BCMA rather than GPRC5D (90-day PFS 38% vs 64%, p = 0.005). This was not attributable to prior BCMA-directed CART or ADC treatment as BCMA-naïve patients fared equally poorly with a BCMA-targeted BsAb #2 (median PFS 36 vs 49 days, p = 0.51). PFS duration with BsAb #1 showed no correlation with PFS on BsAb #2 within individual patients (Spearman ρ = 0.04, p = 0.66). Similarly, there was no correlation between PFS on BCMA- vs GPRC5D-directed BsAbs within individual patients (ρ = 0.08, p = 0.46), indicating that predictors of response and resistance to alternatively targeted BsAbs are likely distinct.
Discussion: Our data suggest that prior treatment with a BsAb in itself neither affects nor predicts treatment outcomes with a subsequent BsAb, provided the second targets a different myeloma antigen. These results implicate target-specific resistance mechanisms as the dominant driver of secondary resistance to BsAbs and do not support a single shared, global driver of resistance across BsAbs with distinct targets. The absence of correlation between PFS with alternatively targeted BsAbs in individual patients suggests that predictors of response are not shared among these therapies. We found no evidence that longer intervals between BsAb treatments improve outcomes, arguing against clinically relevant immune recovery during treatment breaks, and providing no support for delaying subsequent BsAb therapy in the absence of further evidence.
DISCLOSURES
Ross Firestone, MD/PhD: No relevant conflicts of interest to declare.